COPD Drugs Market in China to Grow at a CAGR of 15.56% During the Period 2016-2020

The Report COPD Drugs Market in China 2016-2020 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. -


Albany, NY -- (SBWIRE) -- 07/05/2016 -- About the Chronic Obstructive Pulmonary Disease (COPD) Drugs Market in China

Chronic obstructive pulmonary disease (COPD) is a broad term that covers progressive lung diseases, including emphysema, chronic bronchitis, refractory (non-reversible) asthma, and some forms of bronchiectasis. It restricts airflow in the lungs and is characterized by diffculty breathing. The exact etiology of COPD is not understood, but most cases are caused due to genetic factors and by inhaling pollutants, including smoke, fumes, and chemicals. As the disease develops, the symptoms tend to get worse and damages the lungs. The disease cannot be cured, and can only be managed and treated.

View Full Report at:

The COPD drugs market in China is under penetrated. It is dominated by fixed dose combinations of LABA/ICS. Air pollution is the major contributing factor for the growing prevalence of the disease. Nearly 10% of the population in the region who are over the age of 40 years has COPD. The disease is expected to become one of the leading causes of death in the country by 2020. Lack of awareness about the disease and its treatment options affects the growth of the market in this region.

Technavios analysts forecast the Chronic Obstructive Pulmonary Disease Drugs Market in China to grow at a CAGR of 15.56% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the chronic obstructive pulmonary disease drugs market in China for 2016-2020. To calculate the market size, Technavio considers the revenue generated from the total consumption of the chronic obstructive pulmonary disease drugs globally. The report does not include revenue generated from the aftermarket service of the product.

Download Detail Report With Complete TOC at:

The market is divided into the following segments based on drug class:
Phosphodiesterase-4 (PDE-4) inhibitors
Combination therapies

Technavio's report, Chronic Obstructive Pulmonary Disease (COPD) Drugs Market in China 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
Boehringer Ingelheim
Other prominent vendors
Ache Laboratorios Farmaceuticos
Aquinox Pharmaceuticals
Ario Pharma
BioMarck Pharmaceuticals
Gilead Sciences
Mereo BioPharma Group
Pearl Therapeutics
Teva Pharmaceutical Industry
Theravance Biopharma
Theron Pharmaceuticals
Verona Pharma

Market driver
Increase in environmental pollution
For a full, detailed list, view our report

Market challenge
Low diagnosis rate
For a full, detailed list, view our report

Market trend
Increased focus on combination therapies
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

Browse all latest Press Releases of Market Research Reports at:

About is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Mr. Nachiket
90 Sate Street,
Suite 700 Albany,
NY 12207 USA
Tel: +1-518-621-2074
Canada Toll Free: 866-997-4948